Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Innovation and off-label use, the French case and more.

Literature DB >> 31161633

Innovation and off-label use, the French case and more.

Alain Braillon¹, Joel Lexchin².

Abstract

Keywords: EBM; French National Medical Council; Off-label use; ethics; innovative drugs; quality of care

Mesh：

Year: 2019 PMID： 31161633 PMCID： PMC6783621 DOI： 10.1111/bcp.13993

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

12 in total

Review 1. Accelerated approval of oncology products: the food and drug administration experience.

Authors: John R Johnson; Yang-Min Ning; Ann Farrell; Robert Justice; Patricia Keegan; Richard Pazdur
Journal: J Natl Cancer Inst Date: 2011-03-21 Impact factor: 13.506

2. Innovation and off-label use, the French case and more.

Authors: Alain Braillon; Joel Lexchin
Journal: Br J Clin Pharmacol Date: 2019-06-04 Impact factor: 4.335

3. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?

Authors: Roojin Habibi; Joel Lexchin; Barbara Mintzes; Anne Holbrook
Journal: Br J Clin Pharmacol Date: 2017-08-19 Impact factor: 4.335

Innovation and off-label use, the French case and more.

Review 1. Accelerated approval of oncology products: the food and drug administration experience.

2. Innovation and off-label use, the French case and more.

3. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?

4. Baclofen and alcohol in France.

5. Balancing Accelerated Approval for Drugs With Accelerated Withdrawal.

6. Off-label drug use and temporary recommendations for use: Rearranging the deckchairs on the Titanic?

7. Drug, patient, and physician characteristics associated with off-label prescribing in primary care.

8. An evidence-based systematic review of the off-label uses of lisinopril.

9. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population.

10. The next forum for unraveling FDA off-label marketing rules: State and federal legislatures.

1. Innovation and off-label use, the French case and more.

2. Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin.